Showing results (521-530 of 2,440) with videos related to

Sort By:
Pageof 244
Clinical and Translational Science|March 6, 2024
Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient populationSimon Dagenais, Christine Lee, Carol Cronenberger, et al.
Clinical and Translational Science|March 15, 2024
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysisJian-Hao Deng, Peng-Hui Lai, Li-Shan Xie, et al.
Clinical and Translational Science|March 13, 2024
Plasma sCD146 is a potential biomarker for acute exacerbation of chronic obstructive pulmonary diseaseXinyu Jia, Jingxian Jiang, Chen Yang, et al.
Clinical and Translational Science|March 11, 2024
Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotypingAyako Oda, Yosuke Suzuki, Haruki Sato, et al.
Clinical and Translational Science|March 7, 2024
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonistYun Liu, Wei Wang, Hongjie Qian, et al.
Clinical and Translational Science|March 7, 2024
Tumor biomarkers in evaluating the severity and prognosis of idiopathic pulmonary arterial hypertension: A comprehensive analysisXin Li, Yi Zhang, Sicheng Zhang, et al.
Clinical and Translational Science|March 5, 2024
No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adultsRajinder Bhardwaj, Michael S Hanna, Beth A Morris, et al.
Clinical and Translational Science|February 29, 2024
Knowledge and attitudes on implementing cardiovascular pharmacogenomic testingCallan Russell, MaryAnn Campion, Megan E Grove, et al.
Clinical and Translational Science|February 12, 2024
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritisSumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, et al.
Clinical and Translational Science|February 12, 2024
Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonistErik Rein-Hedin, Folke Sjöberg, Cecilia Ganslandt, et al.
Pageof 244